A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update DOI Creative Commons
Gabriel Samaşcă, Claudia Burz,

Irena Pintea

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(9), P. 1121 - 1121

Published: Aug. 24, 2024

Researchers have performed numerous studies on immunotherapy because of the high death rate associated with gastric cancer (GC). GC research has made tremendous progress, and we wanted to provide an update this topic. On basis update, suggest performing a new medical evaluation before initiating in patients increase success immunotherapies. We propose that start immunotherapy, they should be evaluated given score one two points for following factors: immunopathological features, molecular genomic potential consequences bacterial pathogens, immunotherapeutic resistance hyperprogressive illness, use biomarkers gauge their prognosis responses optimize surgery. The proposed scoring system could also help diagnosis GC. With all advances genetics, immunology, microbiology, improved, not changed. Currently, diagnosed undergo surgical resection as only permanent solution. Patients who meet maximum from presented proposal eligible immediately after immunotherapy. Therefore, first-line option clinicians.

Language: Английский

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers DOI Open Access
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1235 - 1235

Published: Jan. 31, 2025

The PD1/PD-L1 axis plays an important immunosuppressive role during the T-cell-mediated immune response, which is essential for physiological homeostasis of system. biology immunological microenvironment extremely complex and crucial development treatment strategies immunotherapy. Characterization immunological, genomic or transcriptomic landscape cancer patients could allow discrimination between responders non-responders to anti-PD-1/PD-L1 therapy. Immune checkpoint inhibitor (ICI) therapy has shown remarkable efficacy in a variety malignancies landmark trials fundamentally changed Current research focuses on maximize patient selection therapy, clarify mechanisms resistance, improve existing biomarkers, including PD-L1 expression tumor mutational burden (TMB), discover new biomarkers. In this review, we focus function PD-1/PD-L1 signaling pathway discuss genomic, epigenetic receiving Finally, provide overview clinical testing antibodies against PD-1/PD-L1.

Language: Английский

Citations

2
N6-methyladenosine RNA modification in stomach carcinoma: Novel insights into mechanisms and implications for diagnosis and treatment DOI
Zhengmao Lu, Zhaojie Lyu, Peixin Dong

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(5), P. 167793 - 167793

Published: March 14, 2025

Language: Английский

Citations

0
Pan-cancer analysis of the potential of PEA3 subfamily genes as tumor markers DOI Creative Commons
Leying Guan,

Rong Zeng,

Yi Chen

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 28, 2024

Polyomavirus enhancer activator 3 (PEA3), an ETS transcription factor, has been documented to regulate the development and metastasis of human cancers. Nonetheless, a thorough analysis examining relationship between PEA3 subfamily members tumour development, prognosis, microenvironment (TME) across various cancer types not yet conducted. The expression profiles prognostic significance were evaluated using data from GEO, TCGA, PrognoScan databases, in conjunction with COX regression analyses Kaplan-Meier Plotter. Furthermore, relationships expression, stemness scores, tumor microenvironments, immune subtypes, drug susceptibility multiple explored. We found that ETV1, ETV4 ETV5 are highly expressed cancer, their biological functions synergistic. In Cancer Genome Atlas, genes be associated prognosis cancers such as Lung adenocarcinoma (LUAD), Liver hepatocellular carcinoma (LIHC), etc., marked worse at different endpoints. addition, it was significantly correlated stromal scores pan-cancer, also RNA score DNA pan-cancer. Expression levels correlate subtypes LIHC, LUAD, squamous cell carcinoma. variety drugs positive negative associations ETV5. These findings elucidate role gene biomarker for carcinogenesis progression, offering valuable insights future research into potential therapeutic target types.

Language: Английский

Citations

1
A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update DOI Creative Commons
Gabriel Samaşcă, Claudia Burz,

Irena Pintea

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(9), P. 1121 - 1121

Published: Aug. 24, 2024

Researchers have performed numerous studies on immunotherapy because of the high death rate associated with gastric cancer (GC). GC research has made tremendous progress, and we wanted to provide an update this topic. On basis update, suggest performing a new medical evaluation before initiating in patients increase success immunotherapies. We propose that start immunotherapy, they should be evaluated given score one two points for following factors: immunopathological features, molecular genomic potential consequences bacterial pathogens, immunotherapeutic resistance hyperprogressive illness, use biomarkers gauge their prognosis responses optimize surgery. The proposed scoring system could also help diagnosis GC. With all advances genetics, immunology, microbiology, improved, not changed. Currently, diagnosed undergo surgical resection as only permanent solution. Patients who meet maximum from presented proposal eligible immediately after immunotherapy. Therefore, first-line option clinicians.

Language: Английский

Citations

0